NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $196,006 | -23.1% | 10,198 | +1.7% | 0.00% | 0.0% |
| Q2 2023 | $254,836 | -27.7% | 10,025 | +2.8% | 0.00% | -33.3% |
| Q1 2023 | $352,535 | -6.2% | 9,752 | +2.8% | 0.00% | -25.0% |
| Q4 2022 | $375,646 | -11.4% | 9,486 | +4.2% | 0.00% | 0.0% |
| Q3 2022 | $424,000 | +7.3% | 9,103 | +0.9% | 0.00% | 0.0% |
| Q2 2022 | $395,000 | -39.0% | 9,023 | +0.7% | 0.00% | -20.0% |
| Q1 2022 | $648,000 | -10.4% | 8,963 | +0.5% | 0.01% | -16.7% |
| Q4 2021 | $723,000 | -30.9% | 8,915 | -0.9% | 0.01% | -33.3% |
| Q3 2021 | $1,047,000 | -29.4% | 8,999 | +0.6% | 0.01% | -25.0% |
| Q2 2021 | $1,482,000 | +11.6% | 8,941 | -6.1% | 0.01% | 0.0% |
| Q1 2021 | $1,328,000 | -18.8% | 9,521 | +0.7% | 0.01% | -20.0% |
| Q4 2020 | $1,636,000 | +20.6% | 9,453 | -3.0% | 0.02% | +15.4% |
| Q3 2020 | $1,357,000 | +66.5% | 9,745 | +42.8% | 0.01% | +18.2% |
| Q2 2020 | $815,000 | +12.0% | 6,823 | -6.3% | 0.01% | -15.4% |
| Q1 2020 | $728,000 | – | 7,279 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |